|
|
 |
|
Viewing report
|
|
|
|
ratiopharm Generics Company Intelligence Report
Espicom Business Intelligence Ltd, March 2009, Pages: 10
ratiopharm, founded in 1974, claims to be the leading generic company in Germany, and the third largest pharmaceutical company overall, in terms of prescriptions. In January 2009, ratiopharm’s founder died. The VEM Group, which owns ratiopharm, confirmed in early 2009 that the company would be put up for sale. This report provides an insight into the company, reviewing its current business structure and activities.
ratiopharm is a privately-held company owned by the Merckle Group, and based in Ulm, Germany. Founded in 1974, it now claims to be the leading generic company in Germany, and the third largest pharmaceutical company overall, in terms of prescriptions.
Sales in 2007 were 1,819 million euros, of which 819.4 million euros were in Germany, equal to around 45% of the total.
The company also has a major presence in other European countries, such as the UK and the Netherlands. ratiopharm has only a very limited presence in North America, although it has recently been expanding its Canadian operations.
ratiopharm has a generic biologic subsidiary named BioGeneriX. Founded in 2000, BioGeneriX has a number of alliances with potential biogeneric companies around the world. The most advanced project is for G-CSF, developed in collaboration with Neose.
In February 2008, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for two ratiopharm biosimilar medicinal products based on filgrastim.
In January 2009, ratiopharm’s founder died. The VEM Group, which owns ratiopharm, confirmed in early 2009 that the company would be put up for sale.
This report provides information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances and litigation. The company's most recent quarterly and annual financial results are illustrated with comparative figures, charts and a detailed review of the data which allows you to track the company's progress.
Customers who bought this item also bought
Ratiopharm direct GmbH - Strategic Analysis Review
Ratiopharm Pharma Partnering Guide 2008
Ratiopharm IMS Company Profile
Neose Technologies, Inc.
The World Generic Market Report 2008
Emerging Generic Drug Markets in Europe
Neose Technologies Inc. - SWOT Analysis
Neose Technologies Incorporated
Stada Arzneimittel Generics Company Intelligence Report
Neose Technologies, Inc. - Financial and Strategic Analysis Review
Injectable Generic Drugs: Prospects & Opportunities to 2013
Emerging Opportunities in Controlled-Release Generic Drugs
|
|
|
|
